Andere talen Suven Life Sciences Limited

Aandelen

SUVEN

INE495B01038

Beurs gesloten - Bombay S.E. Andere beurzen 12:14:36 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
113,2 ^INR	+0,52%		+1,74%	+40,33%

15/04	Suven Life Sciences presenteert positieve Fase-2-resultaten voor Samelisant (SUVN-G3031) tijdens de jaarlijkse bijeenkomst van de American Academy of Neurology (AAN) 2024 in Denver, VS	CI
06/02	Suven Life Sciences kondigt de randomisatie aan van de eerste patiënt in de Fase-2 POC klinische studie van Ropanicant (SUVN-911) voor de behandeling van matige tot ernstige depressieve stoornissen in de Verenigde Staten	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA	15/04
Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA	06/02
Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024	30/01
Suven Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	30/01
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	04/11
Suven Life Sciences : October 30, 2023Suven Life Sciences announces Positive Topline Results from a Phase-2 study evaluating Samelisant	30-10-23
Suven Life Sciences Announces Positive Topline Results from A Phase-2 Study Evaluating Samelisant (SUVN-G3031) for Excessive Daytime Sleepiness in Adult Narcolepsy Patients with and Without Cataplexy	30-10-23
October 24, 2023Suven Life Sciences Announces Scientific Presentation at CTAD-2023: Study Design of Global Phase-3	24-10-23
Suven Pharma Appoints New Board and Management Team	30-09-23
Suven Pharma Appoints Sudhir Kumar Singh as CEO	30-09-23
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08-08-23
Suven Life Sciences : July 17, 2023Suven Life Announces Clinical and Preclinical data Poster Presentations at AAIC 2023, Amsterdam.	17-07-23
Suven Life Sciences : Form MGT-7 FY 2022-23	15-07-23
Suven Life Sciences : Annual Report FY 2022-23 (Book)	12-07-23
Suven Life Sciences : Annual Report 2022-2023	12-07-23
Suven Life Sciences announces two poster presentations including patient baseline characteristics and demographics from the phase-2 Proof of Concept study on samelisant at the SLEEP-2023 annual meeting	05-06-23
Suven Life Sciences : June 03, 2023Suven announces two poster presentations from the phase-2 (PoC) study on samelisant (SUVN-G3031)	03-06-23
Suven Life Sciences : June 01, 2023Suven completed enrollment of patients to the phase-2(PoC) clinical study of SUVN-G3031 in US,CANADA	01-06-23
Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada	01-06-23
Suven Life Sciences : Schedule of Conference Call for Investors on May 26, 2023	19-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Suven Life Sciences Limited

Aandelen

SUVEN

INE495B01038

Andere talen

Filters